GRTS Gritstone Bio: Enterprise Value-to-Revenue Multiple

Public company logo of Gritstone bio Inc. (GRTS)

Gritstone bio, Inc. (GRTS) has earned physician recognition through its AI-driven neoantigen prediction, although shareholders react sharply to clinical trial milestones. The EV-to-revenue trend reflects current market demand, where is recorded as the baseline value. Intellectual capital in personalized mRNA vaccines creates potential for future payouts from the largest pharma behemoths.

Company Value to Revenue: Gritstone Bio (GRTS) for 07/04/2022 - 11/20/2026

Gritstone Bio - analytical breakdowns and key metrics (GRTS)

- share price and consensus valuation forecast:
Initial company analysis:Gritstone bio Inc. GRTS
Product sample of Gritstone bio Inc.

The selection of promising issuers is based on a multiples analysis, where the key metric is the comparison of total enterprise value to sales volume. This EV/Sales ratio reflects the market valuation of Gritstone bio, Inc. (GRTS) accounting for net debt, which, given its autonomous cGMP facility in California, allows for an assessment of how effectively the company capitalizes its production capacities relative to generated revenue.

Competitor analysis for Gritstone bio, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP